Don't Jump to Spironolactone or Entresto for HFpEF

February 2021

You'll see patients with heart failure with PRESERVED ejection fraction (HFpEF) on spironolactone or sacubitril/valsartan (Entresto).

That's because FDA will likely expand approval of these meds beyond heart failure with REDUCED ejection fraction (HFrEF)...to include some HFpEF patients.

Experts predict these labels may specify HFpEF patients with "mildly reduced" EF, such as about 40% to 50%.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote